Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Cognitive Control in Psychogenic Nonepileptic Seizures
2023-509679-17-00Phase 2Authorised
- Sponsor
- CHU Nîmes
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in Dissociative convulsions (PNES), sponsored by CHU Nîmes. Primary endpoint: Change in cognitive control network activity during emotional Go-No Go task. Planned start May 2024; status: authorised.
02
Drugs
psilocybin
03
Conditions
Dissociative convulsions (PNES)
Beyond the preview
Go deeper on 2023-509679-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509679-17-00.